Page last updated: 2024-08-17

diethylnitrosamine and saroglitazar

diethylnitrosamine has been researched along with saroglitazar in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	1 (100.00)	2.80

Authors

Authors	Studies
Bhoi, B; Giri, SR; Ingale, K; Jain, MR; Kadam, S; Nyska, A; Patel, H; Ranvir, R; Rath, A; Rathod, R; Sharma, A; Trivedi, C	1

Other Studies

1 other study(ies) available for diethylnitrosamine and saroglitazar

Article	Year
Saroglitazar suppresses the hepatocellular carcinoma induced by intraperitoneal injection of diethylnitrosamine in C57BL/6 mice fed on choline deficient, l-amino acid- defined, high-fat diet. BMC cancer, 2023, Jan-17, Volume: 23, Issue:1 Topics: Amino Acids; Animals; Carcinoma, Hepatocellular; Choline; Diet, High-Fat; Diethylnitrosamine; Disease Models, Animal; Injections, Intraperitoneal; Liver; Liver Neoplasms; Mice; Mice, Inbred C57BL; Non-alcoholic Fatty Liver Disease; Peroxisome Proliferator-Activated Receptors	2023

Article

Year

Saroglitazar suppresses the hepatocellular carcinoma induced by intraperitoneal injection of diethylnitrosamine in C57BL/6 mice fed on choline deficient, l-amino acid- defined, high-fat diet.

BMC cancer, 2023, Jan-17, Volume: 23, Issue:1

Topics: Amino Acids; Animals; Carcinoma, Hepatocellular; Choline; Diet, High-Fat; Diethylnitrosamine; Disease Models, Animal; Injections, Intraperitoneal; Liver; Liver Neoplasms; Mice; Mice, Inbred C57BL; Non-alcoholic Fatty Liver Disease; Peroxisome Proliferator-Activated Receptors

2023